Hi, what are you looking for?
By Mary de Wet
PolyPid said Tuesday that it has produced three process-validation batches of D-PLEX, its lead drug candidate to prevent surgical-site infections, putting the company on track to seek regulatory approval.
The Israel-based biopharma company didn’t give a timeline for when it would submit new drug and marketing authorization applications…
Read the full article here
This article was written by Follow Beyond Saving is a professional in commercial real estate providing research on REITs with a focus on properties...
This article was written by Follow I’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared...
